Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10621465 | 0.97 | CYP2D6 (0.41) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| Water SCHEMBL6402454 | 0.97 | CYP3A4 (0.41) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL5438785 | 0.94 | ALDH1A1 (0.40) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL26017608 | 0.94 | CYP2D6 (0.40) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL31049944 | 0.94 | CYP2D6 (0.40) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL450925 | 0.94 | CYP2D6 (0.40) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL1796659 | 0.90 | — | — | |
| SCHEMBL16878844 | 0.90 | SMN1; SMN2 (0.39) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL16877916 | 0.90 | ALDH1A1 (0.39) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 | |
| SCHEMBL1793924 | 0.90 | CYP2D6 (0.41) | CYP2D6CYP3A4ALDH1A1CYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | claimed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | claimed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-1680359-A1 | ZEOLITE SYNTHESIS WITH DIRECTING AGENTS WITH APPROXIMATELY PERPENDICULAR GROUPS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005037713-A1 | ZEOLITE SYNTHESIS WITH DIRECTING AGENTS WITH APPROXIMATELY PERPENDICULAR GROUPS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2005-04-28 | — | — | WO | claimed |
| US-20050084446-A1 | Zeolite synthesis with directing agents with approximately perpendicular groups | SCHMITT KIRK D (US) | 2005-04-21 | — | — | US | claimed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-3743425-B1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| EP-3945091-B1 | NOVEL VDAC1 INHIBITORS | ABARCEO AB (SE) | 2024-01-03 | — | — | EP | disclosed |
| EP-3992196-B1 | 1H-[1, 2, 3]TRIAZOLO[4, 5-H] QUINAZOLINE COMPOUNDS ACTING AS PROTEIN KINASE INHIBITORS | CHENGDU CYNOGEN BIO PHARMACEUTICAL TECH CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2023-11-02 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| WO-2005037713-A1 | ZEOLITE SYNTHESIS WITH DIRECTING AGENTS WITH APPROXIMATELY PERPENDICULAR GROUPS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050084446-A1 | Zeolite synthesis with directing agents with approximately perpendicular groups | SCHMITT KIRK D (US) | 2005-04-21 | — | — | US | disclosed |
| EP-1519939-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept, Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | CYP2D6 363/4885CYP3A4 701/4885ALDH1A1 512/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | CYP2D6 363/4885CYP3A4 701/4885ALDH1A1 512/4885 |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | VDAC1, HVCN1, VDAC2 | CYP2D6 3193/4885CYP3A4 2148/4885ALDH1A1 1308/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP2D6 1847/4885CYP3A4 2444/4885ALDH1A1 1273/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CYP2D6 37/4885CYP3A4 140/4885ALDH1A1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.